Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.

Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H.

Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771.

2.

The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis.

Shimizu T, Morita T, Kumanogoh A.

Rheumatology (Oxford). 2019 Aug 4. pii: kez311. doi: 10.1093/rheumatology/kez311. [Epub ahead of print]

PMID:
31377800
3.

A lung abscess caused by secondary syphilis - the utility of polymerase chain reaction techniques in transbronchial biopsy: a case report.

Futami S, Takimoto T, Nakagami F, Satoh S, Hamaguchi M, Kuroyama M, Miyake K, Koyama S, Iwahori K, Hirata H, Nagatomo I, Takeda Y, Kida H, Kumanogoh A.

BMC Infect Dis. 2019 Jul 9;19(1):598. doi: 10.1186/s12879-019-4236-4.

4.

Response to: 'Blood plasma versus serum: which is right for sampling circulating membrane microvesicles in human subjects?' by Liu et al.

Kato Y, Park J, Takamatsu H, Kumanogoh A.

Ann Rheum Dis. 2019 May 16. pii: annrheumdis-2019-215540. doi: 10.1136/annrheumdis-2019-215540. [Epub ahead of print] No abstract available.

PMID:
31097418
5.

The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors.

Nakai A, Fujimoto J, Miyata H, Stumm R, Narazaki M, Schulz S, Baba Y, Kumanogoh A, Suzuki K.

J Exp Med. 2019 Jul 1;216(7):1630-1647. doi: 10.1084/jem.20181494. Epub 2019 May 14.

6.

Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019.

7.

Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

Arthritis Res Ther. 2019 May 6;21(1):114. doi: 10.1186/s13075-019-1897-8.

8.

Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment.

Masuhiro K, Shiroyama T, Nagatomo I, Kumanogoh A.

J Thorac Oncol. 2019 May;14(5):e108-e109. doi: 10.1016/j.jtho.2018.12.024. No abstract available.

PMID:
31027746
9.

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.

Arthritis Res Ther. 2019 Apr 11;21(1):91. doi: 10.1186/s13075-019-1880-4. Erratum in: Arthritis Res Ther. 2019 May 6;21(1):114.

10.

Transport of cellular misfolded proteins to the cell surface by HLA-B27 free heavy chain.

Yorifuji H, Arase N, Kohyama M, Hirano T, Suenaga T, Kumanogoh A, Arase H.

Biochem Biophys Res Commun. 2019 Apr 16;511(4):862-868. doi: 10.1016/j.bbrc.2019.02.120. Epub 2019 Mar 6.

PMID:
30850159
11.

Roles of Lamtor1 in Macrophages, CD4+ T-cells, and Regulatory T-cells.

Kimura T, Kumanogoh A, Okada M.

Crit Rev Immunol. 2018;38(5):403-414. doi: 10.1615/CritRevImmunol.2018028252.

PMID:
30806216
12.

Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.

Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H.

Sci Rep. 2019 Feb 22;9(1):2636. doi: 10.1038/s41598-019-39345-5.

13.

Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.

Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, Masuhiro K, Yaga M, Iwahori K, Takeda Y, Kida H, Kumanogoh A.

Sci Rep. 2019 Feb 21;9(1):2447. doi: 10.1038/s41598-019-39120-6.

14.

Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis.

Morita T, Shima Y, Fujimoto K, Tsuboi H, Saeki Y, Narazaki M, Ogata A, Kumanogoh A.

Int Immunol. 2019 Apr 26;31(5):277-285. doi: 10.1093/intimm/dxz009.

15.

Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.

Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y.

Oncotarget. 2018 Dec 25;9(101):37520-37533. doi: 10.18632/oncotarget.26494. eCollection 2018 Dec 25.

16.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A.

JCI Insight. 2018 Dec 20;3(24). pii: 123093. doi: 10.1172/jci.insight.123093.

17.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.

Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegawa K, Hosen N, Tsuboi A, Oka Y, Kumanogoh A, Oji Y, Sugiyama H.

Oncotarget. 2018 Nov 13;9(89):36029-36038. doi: 10.18632/oncotarget.26338. eCollection 2018 Nov 13.

18.

OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE.

Mizuno Y, Nishide M, Wakabayashi T, Nishida K, Kumanogoh A.

Ann Rheum Dis. 2018 Nov 28. pii: annrheumdis-2018-214751. doi: 10.1136/annrheumdis-2018-214751. [Epub ahead of print] No abstract available.

PMID:
30487146
19.

Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity.

Sakaue S, Hirata J, Maeda Y, Kawakami E, Nii T, Kishikawa T, Ishigaki K, Terao C, Suzuki K, Akiyama M, Suita N, Masuda T, Ogawa K, Yamamoto K, Saeki Y, Matsushita M, Yoshimura M, Matsuoka H, Ikari K, Taniguchi A, Yamanaka H, Kawaji H, Lassmann T, Itoh M, Yoshitomi H, Ito H, Ohmura K, R Forrest AR, Hayashizaki Y, Carninci P, Kumanogoh A, Kamatani Y, de Hoon M, Yamamoto K, Okada Y.

Nucleic Acids Res. 2018 Dec 14;46(22):11898-11909. doi: 10.1093/nar/gky1066.

20.

SEMA4A promotes eosinophil survival and contributes to eosinophil-mediated allergic diseases.

Maeda Y, Tsuda T, Takeda Y, Koyama S, Hayama Y, Nojima S, Kimura T, Ito D, Takamatsu H, Kang S, Nishide M, Morimoto K, Hosokawa T, Kinehara Y, Kato Y, Nakatani T, Takeda K, Hayama M, Obata S, Akazawa H, Shikina T, Inohara H, Kumanogoh A.

Allergol Int. 2019 Apr;68(2):274-276. doi: 10.1016/j.alit.2018.10.001. Epub 2018 Oct 19. No abstract available.

21.

Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.

Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, Naito Y, Otsuka T, Kanazu M, Kuroyama M, Hamaguchi M, Koba T, Futami Y, Ishijima M, Suga Y, Akazawa Y, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, Mori M, Kijima T, Kumanogoh A.

JCI Insight. 2018 Oct 4;3(19). pii: 59125. doi: 10.1172/jci.insight.59125.

22.

Long-term outcomes of advanced thymoma in patients undergoing preoperative chemotherapy or chemoradiotherapy followed by surgery: a 20-year experience.

Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, Minami M, Kida H, Ogawa K, Kumanogoh A, Okumura M.

Interact Cardiovasc Thorac Surg. 2019 Mar 1;28(3):360-367. doi: 10.1093/icvts/ivy276.

PMID:
30256943
23.

Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity.

Tsuda T, Maeda Y, Nishide M, Koyama S, Hayama Y, Nojima S, Takamatsu H, Okuzaki D, Kinehara Y, Kato Y, Nakatani T, Obata S, Akazawa H, Shikina T, Takeda K, Hayama M, Inohara H, Kumanogoh A.

Int Immunol. 2019 Feb 6;31(1):33-40. doi: 10.1093/intimm/dxy061.

24.

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment.

Koyama S, Nagatomo I, Kijima T, Kumanogoh A.

Oncotarget. 2018 Aug 24;9(66):32552-32553. doi: 10.18632/oncotarget.26028. eCollection 2018 Aug 24. No abstract available.

25.

Ficolin-1 is a promising therapeutic target for autoimmune diseases.

Katayama M, Ota K, Nagi-Miura N, Ohno N, Yabuta N, Nojima H, Kumanogoh A, Hirano T.

Int Immunol. 2019 Feb 6;31(1):23-32. doi: 10.1093/intimm/dxy056.

26.

Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.

Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, Ueda M, Nishide M, Koyama S, Hayama Y, Kinehara Y, Hirano T, Shima Y, Narazaki M, Kumanogoh A.

Ann Rheum Dis. 2018 Oct;77(10):1507-1515. doi: 10.1136/annrheumdis-2018-212988. Epub 2018 Jun 26.

27.

The Direct Oblique Method: A New Gold Standard for Bronchoscopic Navigation That is Superior to Automatic Methods.

Miyake K, Morimura O, Inoue T, Yoshida K, Nagatomo I, Kijima T, Kumanogoh A.

J Bronchology Interv Pulmonol. 2018 Oct;25(4):305-314. doi: 10.1097/LBR.0000000000000512.

PMID:
29901530
28.

Semaphorin 6D reverse signaling controls macrophage lipid metabolism and anti-inflammatory polarization.

Kang S, Nakanishi Y, Kioi Y, Okuzaki D, Kimura T, Takamatsu H, Koyama S, Nojima S, Nishide M, Hayama Y, Kinehara Y, Kato Y, Nakatani T, Shimogori T, Takagi J, Toyofuku T, Kumanogoh A.

Nat Immunol. 2018 Jun;19(6):561-570. doi: 10.1038/s41590-018-0108-0. Epub 2018 May 18.

PMID:
29777213
29.

In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption.

Matsuura Y, Kikuta J, Kishi Y, Hasegawa T, Okuzaki D, Hirano T, Minoshima M, Kikuchi K, Kumanogoh A, Ishii M.

Ann Rheum Dis. 2018 Aug;77(8):1219-1225. doi: 10.1136/annrheumdis-2017-212880. Epub 2018 Apr 28.

PMID:
29705743
30.

Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder.

Yamashita K, Kinoshita M, Miyamoto K, Namba A, Shimizu M, Koda T, Sugimoto T, Mori Y, Yoshioka Y, Nakatsuji Y, Kumanogoh A, Kusunoki S, Mochizuki H, Okuno T.

J Neuroinflammation. 2018 Apr 27;15(1):125. doi: 10.1186/s12974-018-1162-0.

31.

Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EB.

Hayama Y, Kimura T, Takeda Y, Nada S, Koyama S, Takamatsu H, Kang S, Ito D, Maeda Y, Nishide M, Nojima S, Sarashina-Kida H, Hosokawa T, Kinehara Y, Kato Y, Nakatani T, Nakanishi Y, Tsuda T, Koba T, Okada M, Kumanogoh A.

J Immunol. 2018 Jun 1;200(11):3790-3800. doi: 10.4049/jimmunol.1701283. Epub 2018 Apr 23.

32.

Correction for Toyofuku et al., "Leucine-Rich Repeat Kinase 1 Regulates Autophagy through Turning On TBC1D2-Dependent Rab7 Inactivation".

Toyofuku T, Morimoto K, Sasawatari S, Kumanogoh A.

Mol Cell Biol. 2018 Mar 29;38(8). pii: e00079-18. doi: 10.1128/MCB.00079-18. Print 2018 Apr 15. No abstract available.

33.

Double deletion of tetraspanins CD9 and CD81 in mice leads to a syndrome resembling accelerated aging.

Jin Y, Takeda Y, Kondo Y, Tripathi LP, Kang S, Takeshita H, Kuhara H, Maeda Y, Higashiguchi M, Miyake K, Morimura O, Koba T, Hayama Y, Koyama S, Nakanishi K, Iwasaki T, Tetsumoto S, Tsujino K, Kuroyama M, Iwahori K, Hirata H, Takimoto T, Suzuki M, Nagatomo I, Sugimoto K, Fujii Y, Kida H, Mizuguchi K, Ito M, Kijima T, Rakugi H, Mekada E, Tachibana I, Kumanogoh A.

Sci Rep. 2018 Mar 23;8(1):5145. doi: 10.1038/s41598-018-23338-x.

34.

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.

Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H.

PLoS One. 2018 Mar 15;13(3):e0194130. doi: 10.1371/journal.pone.0194130. eCollection 2018.

35.

Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.

Koda T, Namba A, Nakatsuji Y, Niino M, Miyazaki Y, Sugimoto T, Kinoshita M, Takata K, Yamashita K, Shimizu M, Fukazawa T, Kumanogoh A, Mochizuki H, Okuno T.

PLoS One. 2018 Mar 8;13(3):e0193986. doi: 10.1371/journal.pone.0193986. eCollection 2018.

36.

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.

Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H.

Cancer Immunol Res. 2018 Mar;6(3):320-331. doi: 10.1158/2326-6066.CIR-17-0386. Epub 2018 Jan 22.

37.

WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H.

Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.

38.

Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.

Takeuchi Y, Tanemura A, Tada Y, Katayama I, Kumanogoh A, Nishikawa H.

Int Immunol. 2018 Feb 3;30(1):13-22. doi: 10.1093/intimm/dxx073.

PMID:
29294043
39.

Quantitative pulmonary blood flow measurement using 15O-H2O PET with and without tissue fraction correction: a comparison study.

Matsunaga K, Yanagawa M, Otsuka T, Hirata H, Kijima T, Kumanogoh A, Tomiyama N, Shimosegawa E, Hatazawa J.

EJNMMI Res. 2017 Dec 22;7(1):102. doi: 10.1186/s13550-017-0350-8.

40.

The role of semaphorins in immune responses and autoimmune rheumatic diseases.

Nishide M, Kumanogoh A.

Nat Rev Rheumatol. 2018 Jan;14(1):19-31. doi: 10.1038/nrrheum.2017.201. Epub 2017 Dec 7. Review.

PMID:
29213125
41.

Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.

Honorat JA, Nakatsuji Y, Shimizu M, Kinoshita M, Sumi-Akamaru H, Sasaki T, Takata K, Koda T, Namba A, Yamashita K, Sanda E, Sakaguchi M, Kumanogoh A, Shirakura T, Tamura M, Sakoda S, Mochizuki H, Okuno T.

PLoS One. 2017 Nov 6;12(11):e0187215. doi: 10.1371/journal.pone.0187215. eCollection 2017.

42.

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.

Nat Med. 2017 Dec;23(12):1436-1443. doi: 10.1038/nm.4431. Epub 2017 Nov 6.

PMID:
29106400
43.

Tracheobronchopathia Osteochondroplastica: A Cause of Difficult Tracheal Intubation.

Matsuki T, Takeda Y, Kida H, Kumanogoh A.

Intern Med. 2018 Mar 15;57(6):909-910. doi: 10.2169/internalmedicine.9336-17. Epub 2017 Nov 1. No abstract available.

44.

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H.

Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18. Review.

45.

Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis.

Morita T, Fujimoto K, Shima Y, Ogata A, Kumanogoh A.

Ann Rheum Dis. 2018 Sep;77(9):e56. doi: 10.1136/annrheumdis-2017-212366. Epub 2017 Sep 22. No abstract available.

PMID:
28939633
46.

Gallbladder-derived surfactant protein D regulates gut commensal bacteria for maintaining intestinal homeostasis.

Sarashina-Kida H, Negishi H, Nishio J, Suda W, Nakajima Y, Yasui-Kato M, Iwaisako K, Kang S, Endo N, Yanai H, Asagiri M, Kida H, Hattori M, Kumanogoh A, Taniguchi T.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10178-10183. doi: 10.1073/pnas.1712837114. Epub 2017 Sep 6.

47.

CUBIC pathology: three-dimensional imaging for pathological diagnosis.

Nojima S, Susaki EA, Yoshida K, Takemoto H, Tsujimura N, Iijima S, Takachi K, Nakahara Y, Tahara S, Ohshima K, Kurashige M, Hori Y, Wada N, Ikeda JI, Kumanogoh A, Morii E, Ueda HR.

Sci Rep. 2017 Aug 24;7(1):9269. doi: 10.1038/s41598-017-09117-0.

48.

Lamtor1 Is Critically Required for CD4+ T Cell Proliferation and Regulatory T Cell Suppressive Function.

Hosokawa T, Kimura T, Nada S, Okuno T, Ito D, Kang S, Nojima S, Yamashita K, Nakatani T, Hayama Y, Kato Y, Kinehara Y, Nishide M, Mikami N, Koyama S, Takamatsu H, Okuzaki D, Ohkura N, Sakaguchi S, Okada M, Kumanogoh A.

J Immunol. 2017 Sep 15;199(6):2008-2019. doi: 10.4049/jimmunol.1700157. Epub 2017 Aug 2.

49.

Control of species-dependent cortico-motoneuronal connections underlying manual dexterity.

Gu Z, Kalambogias J, Yoshioka S, Han W, Li Z, Kawasawa YI, Pochareddy S, Li Z, Liu F, Xu X, Wijeratne HRS, Ueno M, Blatz E, Salomone J, Kumanogoh A, Rasin MR, Gebelein B, Weirauch MT, Sestan N, Martin JH, Yoshida Y.

Science. 2017 Jul 28;357(6349):400-404. doi: 10.1126/science.aan3721.

50.

Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.

Shiroyama T, Tamiya M, Minami S, Takata S, Masuhiro K, Futami-Nishijima Y, Uenami T, Mori M, Koba T, Matsuki T, Takimoto T, Suzuki H, Okamoto N, Komuta K, Hirashima T, Kumanogoh A, Kijima T.

Cancer Chemother Pharmacol. 2017 Sep;80(3):461-467. doi: 10.1007/s00280-017-3385-7. Epub 2017 Jul 7.

PMID:
28688052

Supplemental Content

Loading ...
Support Center